Saturday, 10 June 2017

Pure Telecom puts growth in focus

Pure Telecom announces it has signed a €1.75 million two-year deal with sales agency DSM. The deal will allow DSM to recruit 15 sales representatives, who will be tasked with growing Pure Telecom’s business across the country, with a particular focus on rural Ireland.

Pure Telecom has agreements with several of Ireland’s major wholesale telecoms providers, allowing it to bring broadband to residential customers as soon as fibre networks are laid. Much of the telco’s recent business growth has been achieved through the increased rollout of rural broadband by its wholesale partners. The company currently has more than 45,000 residential customers and has plans to more than double that number to 100,000 by the end of 2019.

As nationwide fibre rollouts continue, and in anticipation of a decision on the National Broadband Plan, Pure Telecom requires an increased presence of sales agents in key locations across Ireland to help it achieve its aggressive growth plan.

All of the DSM positions will be field sales roles and successful candidates will have customer-facing experience and a track record in achieving ambitious sales targets. The sales representatives will receive ongoing training from DSM.

Paul Connell, CEO, Pure Telecom, said: “This deal is part of our nationwide push to bring broadband to a lot more people and households in rural Ireland. We work very closely with some of Ireland’s major wholesale providers and want to ensure that we are there as soon as the broadband is. Part of that means having an increased presence of sales representatives and we are very confident that this deal with DSM will play a significant role in helping us to grow our business and footprint outside of the major cities.

“We have already seen a significant uptake in broadband services in the areas that are being served by private and government-funded fibre rollouts and we are committed to playing our part in increasing those numbers. Like everyone else, we eagerly await news on the National Broadband Plan. Rural Ireland has been waiting long enough to get connected and we encourage the Government to announce its decision on the remaining premises that are not included in any rollout very soon.

“What we have found interesting is that as more people become connected to broadband, the fixed line is making a comeback. A few years ago most people thought that the smartphone would see the demise of the landline and we prepared ourselves for that, but instead we are seeing huge demand for it. The National Broadband Plan will only serve to increase that demand.”

James Edinborough, CEO, DSM Ltd, added: “Pure Telecom is the kind of company that sales representatives want to work with because of its dedication to customer service and competitive pricing. Broadband across Ireland still has a long way to go, but we look forward to helping Pure Telecom roll out the much-needed service across the country.

“Our relationship with Pure Telecom spans many years and we are delighted to have signed another deal with them. We look forward to providing Pure Telecom with the best in class sales support to help it continue on its impressive growth path.”

Friday, 9 June 2017

EU Catch Project findings released

European cancer researchers to present their research on technology enabled cancer rehabilitation as part of €2.1 million EU project CATCH in University College Dublin.

Researchers from the CATCH programme (Cancer Activating Technologies for Connected Health), an EU project led by Professor Brian Caulfield, Director of Insight (Insight Centre for Data Analytics) at UCD will present their research projects on technology innovations for cancer rehabilitation. CATCH has finalised the international recruitment process for 8 Marie Curie- Sklodowska PhD students and they will all be presenting their research projects on Friday 9th June 2017 at 10.30am to 1.00pm in the O'Brien Science Centre, UCD, Dublin.

CATCH (Cancer Activating Technology in Connected Health) is an international consortium, led by UCD, Professor Brian Caulfield in Insight, with academia, industry and healthcare providers across Europe. Professor Caulfield is a leading expert in Connected Health and the use of technology to provide the most effective and efficient personalised healthcare.

Professor Brian Caulfield said:

“Over the past 10 years, advances in cancer diagnosis and treatment have been ground-breaking. CATCH will join in the fight against cancer and will provide a much needed interdisciplinary training and research programme.

Through the implementation of successful research results and discoveries in cancer care, we are now able to consider certain cancers as a chronic disease, rather than a fatal illness. Moving forward, CATCH is joining this fight to ensure that we can offer the tools needed to maximize the impact of the rehabilitation programs for those living with this disease on their journey back to a full and active life.”

The focus of CATCH is to improve the care pathways for patients living with cancer in Ireland, Europe and Globally through its training and research programme.

CATCH is a deep collaboration across academic, business and clinical sectors. Students will benefit from intersectoral secondments, interdisciplinary communication skills, public engagement and outreach while working on a programme of interrelated core research projects addressing gaps in the knowledge and evidence base for technology enabled cancer rehabilitation.

This innovative training programme is funded by European Union’s Horizon 2020 programme under the Marie SkÅ‚odowska-Curie actions initiative.

Lero DkIT spinout company Nova Leah to create 78 jobs

Lero researchers from the Regulated Research Centre at Dundalk Institute of Technology have launched a new medical device cybersecurity company that plans to create 78 jobs over the next four years. The Lero DkIT spinout company, Nova Leah (www.novaleah.com) has developed an expert cybersecurity risk management software application aimed at global medical device manufacturers and healthcare providers.

Nova Leah, has just opened an office in Boston to serve the North American market. Initial investors include US venture capital company COSIMO Venture Partners and Enterprise Ireland.

“We believe that cybersecurity for medical devices will be a significant new market,” said Rob Frasca of COSIMO Venture Partners. “A first of its kind, we are not aware of any other company worldwide that can provide medical device manufacturers with an automated solution to implement and maintain cybersecurity requirements across medical device product portfolios.”

“The recent WannaCry ransomware attack on the UK’s NHS highlights the importance of cybersecurity in the health sector. Today’s medical devices incorporate high levels of software and are connected across networks, online or wirelessly,” commented Nova Leah CEO, Anita Finnegan.

“As a result, medical device manufacturers are facing two major challenges: ensuring compliance with stricter regulatory measures and minimising the probability of malicious breaches aimed at medical devices and healthcare IT networks.”

The new cloud based system, SelectEvidence®, which follows a five-year R&D programme at Dundalk Institute of Technology, is designed to guide medical device manufacturers implementing cybersecurity requirements and best practices over the lifetime of device in compliance with US FDA (Food & Drug Administration) recommendations for information security threats and risks during premarket and post market activities.

Anita Finnegan added that data breaches in the US are estimated to be costing healthcare providers $5.6 billion annually*. Nova Leah is initially targeting customers in the imaging and electro medical device sectors in the US, a market that is estimated to be worth $155 billion of which connected devices account for approximately $51 billion. It is estimated that there are more than 6,500 medical device manufacturers in the US.**
Lero researcher Dr Fergal McCaffery, based at Dundalk Institute of Technology, a non-executive director of the new firm added, “SelectEvidence® ensures speedier market deployment for devices, reduced compliance costs and fewer market recalls due to data hacks; all of which boost profitability of our target organisations.”

One of Nova Leah’s first customers is an Irish based device manufacturer, Orreco.

“Orreco holds biomarker and other information on elite and professional athletes. Security, compliance and data protection is therefore a priority,” commented Fiona Slevin, COO. “Using SelectEvidence® we were able to design our software platform to global security standards, thus strengthening our confidence in the features designed to optimise security, safety and protection of data.”

“The launch of this spinout company is further evidence of the quality and global potential of the software research being carried out across the Lero organisation,” commented Professor Brian Fitzgerald, director, Lero – the Irish Software Research Centre, which is supported by Science Foundation Ireland. “It also emphasises the national asset in terms of medical device research that is based at the Dundalk Institute of Technology.”

Dr Joe Healy, Divisional Manager, High Potential Start Up Division, Enterprise Ireland, added, “Enterprise Ireland’s mission is to partner with innovative Irish businesses and entrepreneurs with the drive and ambition to scale in international markets. Enterprise Ireland has worked closely with Dr Anita Finnegan over the past five years and seen first-hand how the college based research and then the start-up company Nova Leah has gone from strength to strength. Enterprise Ireland looks forward to working with Nova Leah to continue to support their growth ambitions as they strengthen their customer base and grow internationally.”

Anita Finnegan has over 15 years’ experience working in regulated environments such as medical devices, automotive and construction. She is an international project leader with ISO/IEC SC62a Joint Working Group 7 and Working Group 4. Nominated by NSAI, she also represents Ireland as the medical device security expert at international standards meetings. Her PhD research provided the basis for Nova Leah’s SelectEvidence® product.

Dr. Fergal McCaffery is a Science Foundation Ireland (SFI) principal investigator. He is director of the Regulated Software Research Centre (RSRC) in Dundalk Institute of Technology and the medical device software engineering competency area leader in Lero, the Irish Software Research Centre which is supported by SFI.

Lero, the Irish Software Research Centre (www.lero.ie) is a global leader in software research. It combines the best in Irish software talent by bringing together researchers from Dublin City University, Dundalk Institute of Technology, NUI Galway, Maynooth University, Trinity College Dublin, University College Cork, University College Dublin and University of Limerick. It is funded by Science Foundation Ireland as well as by contracts from Irish and international technology corporations.